:quality(90))
Welcome to an enlightening conversation with Dr. Damian Okruciński, a distinguished graduate of the Medical University of Warsaw, a specialist of pediatrics, specializing in vaccinology and exhibiting a profound passion for travel medicine. His expansive expertise extends across borders, earning him recognition as a member of the Polish Society of Vaccinology, the Polish Society of Pediatrics, and the European Society of Pediatric Infectious Diseases.
Our discussion today delves into the pivotal realm of Clinical Trials, with a specific focus on the poignant subject of pediatric migraine research. In a world where pediatric healthcare is rapidly advancing, these Clinical Trials emerge as beacons of hope, poised to revolutionize the lives of children and their families.
In the heart of this transformative landscape is Pratia, where the patient, takes center stage. Dr. Okruciński underscores the commitment to ensuring that both children and parents feel genuinely cared for and supported. The emphasis on trust and a shared understanding of the trial’s purpose creates an environment where the well-being of each participant is priority.
Join us as we navigate this crucial dialogue with Dr. Damian Okruciński, where professionalism, empathy, and the pursuit of a brighter, healthier future for children seamlessly intertwine within the context of groundbreaking migraine research in pediatric clinical trials.
PRATIA: Thank you for joining us today. To start, could you present the overview of this Clinical Trial, including its goals and scope?
Dr. Damian Okruciński: Certainly! This groundbreaking Clinical Trial aims to revolutionize migraine treatment for adolescents aged 12 to 18, introducing a sublingual tablet administered every two days. With a focus on chronic migraines, this highly effective medication not only alleviates symptoms but also stands as a beacon of prevention, a vital aspect often overlooked in current treatments. While the broader plan includes extending its benefits to children as young as 8, our current emphasis is on refining the well-being of those aged 12-18.
PRATIA: What motivated you to conduct this study, and why is it significant in the field of medicine?
Dr. Damian Okruciński: The inspiration behind this study stems from the alarming scarcity of effective migraine treatments tailored for young individuals. Imagine the transformative impact on adolescents who endure up to 20 migraine days a month. This is a poignant issue, affecting their self-esteem, hindering their passions, and disrupting their academic journey. Our pursuit is to offer not just relief but an opportunity for children and teenagers to live fuller lives.
PRATIA: Could you share insights into the challenges that may arise during the study involving children?
Dr. Damian Okruciński: Clinical Trials involving children unveils a dual challenge, with both the young participants and their parents at the forefront. The recurrent need for blood draws, a necessary component, can be an anxiety-inducing experience for children. On the parental side, commitments to frequent visits might present logistical hurdles. However, effective communication becomes the linchpin—providing comprehensive information and underlining the study’s purpose helps parents recognize that this medication could be a game-changer, surpassing currently available symptomatic treatments.
PRATIA: How does Pratia address these challenges?
Dr. Damian Okruciński: At Pratia, our commitment is unwavering—the patient is paramount. Our Sites are meticulously designed to foster a comforting and secure atmosphere for those partaking in Clinical Trials. From the aesthetics of our Sites to the demeanor of our staff, everything is crafted to ensure that participants, especially children, feel at ease. Pratia is more than just a research center; it’s a haven dedicated to positively impacting lives.
PRATIA: In what ways can the results of this study benefit pediatric patients and their families in the future?
Dr. Damian Okruciński: The outcomes of this study hold the promise of transformative benefits for both the young participants and their immediate circles. Imagine a child liberated from migraines, free to pursue their passions, engage socially, and excel academically. This isn’t just about treating a medical condition; it’s about providing the space for a child’s natural and joyous development without the burden of chronic migraines.
PRATIA: What would you say to parents who may have concerns about enrolling their children in clinical trials, and how can Pratia’s Patient Engagement team address these concerns?
Dr. Damian Okruciński: I would like to emphasise that the safety of the child is the most crucial issue for us. Clinical Trials are not about experimentation but rather about paving the way for groundbreaking solutions. The meticulous approach of our Patient Engagement team ensures that parents are well-informed, reassured, and confident in their decision to entrust their child’s care to Pratia.
PRATIA: What are the most satisfying aspects for you in conducting this study for pediatric patients?
Dr. Damian Okruciński: On one hand, the gratification stems from witnessing tangible improvements in a patient’s life—seeing the medication’s efficacy translate into a positive transformation. On the other, the moment when this medication reaches the market and extends its helping hand to a broader audience is deeply fulfilling. It’s not just about individual success stories but contributing to a collective improvement in healthcare.
PRATIA: Looking ahead, how do you envision the future of pediatric clinical trials, and what role will this study play in shaping that future?
Dr. Damian Okruciński: Envisioning the future of pediatric Clinical Trials, my hope is for an exponential increase in the number of trials dedicated to children’s health. The demand for diverse medications for children is substantial, and Clinical Trials serve as a beacon of hope for those in need. As for this study, it’s not just about treating migraines; it’s about setting a precedent for comprehensive pediatric healthcare solutions. Additionally, our upcoming clinical trials on vaccines represent our commitment to advancing healthcare on a grand scale—an immediate future we’re excited to embark on.
PRATIA: Thank you for sharing these profound insights with us today, Dr. Okruciński. The significance of this clinical trial in transforming the landscape of pediatric healthcare is truly inspiring. As we bring this enlightening conversation to a close, it becomes clear that the journey we embark on today holds the potential to shape a brighter future for countless children and their families.
Dr. Okruciński’s commitment to revolutionizing migraine treatment for adolescents and his vision for the future of pediatric clinical trials exemplify the unwavering dedication at Pratia. In the heart of it all lies the holistic approach, where the well-being of each patient, young or old, is at the forefront.
:quality(90))